JP2012521768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012521768A5 JP2012521768A5 JP2012502294A JP2012502294A JP2012521768A5 JP 2012521768 A5 JP2012521768 A5 JP 2012521768A5 JP 2012502294 A JP2012502294 A JP 2012502294A JP 2012502294 A JP2012502294 A JP 2012502294A JP 2012521768 A5 JP2012521768 A5 JP 2012521768A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- binding protein
- bispecific binding
- cancer
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000023732 binding proteins Human genes 0.000 claims 17
- 108091008324 binding proteins Proteins 0.000 claims 17
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 9
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 9
- 108091008794 FGF receptors Proteins 0.000 claims 7
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims 7
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 5
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims 3
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 206010073363 Acinar cell carcinoma of pancreas Diseases 0.000 claims 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000024558 digestive system cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 201000010231 gastrointestinal system cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000010287 pancreatic acinar cell adenocarcinoma Diseases 0.000 claims 1
- 208000030352 pancreatic acinar cell carcinoma Diseases 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16402309P | 2009-03-27 | 2009-03-27 | |
| US61/164,023 | 2009-03-27 | ||
| PCT/US2010/028877 WO2010111625A1 (en) | 2009-03-27 | 2010-03-26 | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012521768A JP2012521768A (ja) | 2012-09-20 |
| JP2012521768A5 true JP2012521768A5 (OSRAM) | 2013-05-09 |
Family
ID=42332479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012502294A Pending JP2012521768A (ja) | 2009-03-27 | 2010-03-26 | 抗体−受容体の組み合わせを含む多特異的結合性タンパク質を用いるための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120134993A1 (OSRAM) |
| EP (1) | EP2411407A1 (OSRAM) |
| JP (1) | JP2012521768A (OSRAM) |
| KR (1) | KR20110134494A (OSRAM) |
| CN (1) | CN102448984A (OSRAM) |
| AU (1) | AU2010229705A1 (OSRAM) |
| MX (1) | MX2011009810A (OSRAM) |
| WO (1) | WO2010111625A1 (OSRAM) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
| MX2015012778A (es) * | 2013-03-15 | 2016-01-20 | Intermune Inc | Marcadores proteomicos de fibrosis pulmonar idiopatica (fpi). |
| EP3013851A4 (en) * | 2013-06-25 | 2016-12-28 | Sépia Pesquisa E Desenvolvimento | MODULATORS OF BRADYKININ RECEPTORS AND THEIR USE |
| US9879081B2 (en) | 2013-06-25 | 2018-01-30 | Samsung Electronics Co., Ltd. | Protein complex, bispecific antibody including the protein complex, and method of preparation thereof |
| KR102060187B1 (ko) | 2013-07-19 | 2019-12-27 | 삼성전자주식회사 | Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도 |
| PL3041513T3 (pl) | 2013-09-08 | 2021-01-25 | Kodiak Sciences Inc. | Obojnaczojonowe polimerowe koniugaty czynnika viii |
| WO2015200905A2 (en) * | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CN104177492B (zh) * | 2014-07-21 | 2017-02-22 | 暨南大学 | FGFR2c胞外段类似物及其编码基因与应用 |
| CN113957146A (zh) | 2014-09-26 | 2022-01-21 | 詹森药业有限公司 | 使用fgfr突变基因组鉴定将对用fgfr抑制剂进行治疗有反应的癌症患者 |
| KR102210104B1 (ko) | 2014-10-17 | 2021-02-01 | 코디악 사이언시스 인코포레이티드 | 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트 |
| US12428483B2 (en) | 2014-12-22 | 2025-09-30 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| WO2016106158A1 (en) | 2014-12-22 | 2016-06-30 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| UA128057C2 (uk) | 2015-07-15 | 2024-03-27 | Ґенмаб А/С | Гуманізоване або химерне антитіло, яке зв'язує cd3 людини |
| WO2017091850A1 (en) * | 2015-11-30 | 2017-06-08 | Pieris Australia Pty Ltd. | Novel anti-angiogenic fusion polypeptides |
| CA3010056A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| WO2018011421A1 (en) | 2016-07-14 | 2018-01-18 | Genmab A/S | Multispecific antibodies against cd40 and cd137 |
| PT3592769T (pt) | 2017-03-09 | 2024-07-31 | Genmab As | Anticorpos contra pd-l1 |
| UA127586C2 (uk) | 2017-03-31 | 2023-10-25 | Ґенмаб Холдінґ Б.В. | Біспецифічні анти-cd37-антитіла, моноклональні анти-cd37-антитіла та способи їх застосування |
| CN111406067B (zh) | 2017-08-04 | 2022-11-08 | 健玛保 | 与pd-l1和cd137结合的结合剂及其用途 |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| US12077586B2 (en) | 2018-09-19 | 2024-09-03 | LAVA Therapeutics N.V. | Bispecific antibodies for use in the treatment of hematological malignancies |
| MA53812A (fr) | 2018-10-04 | 2021-08-11 | Genmab Holding B V | Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques |
| KR20210124959A (ko) | 2018-11-06 | 2021-10-15 | 젠맵 에이/에스 | 항체 제제 |
| NL2022494B1 (en) | 2019-02-01 | 2020-08-19 | Lava Therapeutics B V | Novel CD40-binding antibodies |
| EP3917960A1 (en) | 2019-02-01 | 2021-12-08 | LAVA Therapeutics N.V. | Novel cd40-binding antibodies |
| JPWO2021010326A1 (OSRAM) * | 2019-07-12 | 2021-01-21 | ||
| EP3792283A1 (en) | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| WO2021155916A1 (en) | 2020-02-04 | 2021-08-12 | BioNTech SE | Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137 |
| MY210125A (en) | 2020-03-18 | 2025-08-28 | Genmab As | Antibodies binding to b7h4 |
| JP2023524149A (ja) | 2020-05-08 | 2023-06-08 | ジェンマブ エー／エス | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
| US20230272110A1 (en) | 2020-07-08 | 2023-08-31 | LAVA Therapeutics N.V. | Antibodies that bind psma and gamma-delta t cell receptors |
| JP2023536340A (ja) | 2020-08-06 | 2023-08-24 | ビオンテック・ソシエタス・エウロパエア | コロナウイルスｓタンパク質のための結合剤 |
| BR112023004327A2 (pt) | 2020-09-10 | 2023-04-04 | Genmab As | Método para tratar leucemia linfocítica crônica em um sujeito humano |
| MX2023002545A (es) | 2020-09-10 | 2023-03-14 | Genmab As | Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para el tratamiento de linfoma difuso de celulas b grandes. |
| JP2024501403A (ja) | 2020-12-10 | 2024-01-12 | ラヴァ・セラピューティクス・エヌ・ヴイ | ガンマ－デルタｔ細胞受容体に結合する抗体 |
| US20240141071A1 (en) | 2021-02-26 | 2024-05-02 | LAVA Therapeutics N.V. | Antibodies that bind cd123 and gamma-delta t cell receptors |
| US20240383982A1 (en) | 2021-05-07 | 2024-11-21 | Genmab A/S | Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3 |
| IL309319A (en) | 2021-06-21 | 2024-02-01 | Genmab As | Combined dosage regimen CD137 and PD-L1 binding agents |
| TW202328193A (zh) | 2021-09-13 | 2023-07-16 | 美商健生生物科技公司 | 用於治療癌症的CD33 x Vδ2多特異性抗體 |
| AU2022361691A1 (en) | 2021-10-08 | 2024-03-28 | Genmab A/S | Antibodies binding to cd30 and cd3 |
| EP4419109A1 (en) | 2021-10-21 | 2024-08-28 | LAVA Therapeutics N.V. | Uses of gamma delta t cell activating antibodies |
| WO2023174521A1 (en) | 2022-03-15 | 2023-09-21 | Genmab A/S | Binding agents binding to epcam and cd137 |
| EP4285926A1 (en) | 2022-05-30 | 2023-12-06 | LAVA Therapeutics N.V. | Combination treatment for chronic lymphocytic leukemia |
| EP4292609A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Compositions comprising antibodies that bind gamma-delta t cell receptors |
| EP4292610A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| NL2032398B1 (en) | 2022-07-06 | 2024-01-23 | Academisch Ziekenhuis Leiden | Bispecific antibody and uses thereof |
| CN118420715B (zh) * | 2023-03-23 | 2025-01-24 | 湖南中晟全肽生物科技股份有限公司 | 一种结合fgfr2受体的多肽及其用途 |
| EP4438624A1 (en) | 2023-03-27 | 2024-10-02 | LAVA Therapeutics N.V. | Antibodies that bind nectin-4 and gamma-delta t cell receptors |
| WO2024200573A1 (en) | 2023-03-27 | 2024-10-03 | LAVA Therapeutics N.V. | Nectin-4 binding agents and methods of use |
| AR132290A1 (es) | 2023-04-05 | 2025-06-11 | Genmab As | Composiciones farmacéuticas que comprenden anticuerpos que se unen a cd30 y cd3 |
| WO2025003280A1 (en) | 2023-06-30 | 2025-01-02 | Genmab A/S | Antibodies binding to fibroblast activation protein alpha and death receptor 4 |
| WO2025012118A2 (en) | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| WO2025024780A1 (en) | 2023-07-27 | 2025-01-30 | LAVA Therapeutics N.V. | Antibodies that bind gamma-delta t cell receptors for the treatment of cancer |
| WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004536579A (ja) * | 2001-04-13 | 2004-12-09 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 血管内皮増殖因子２ |
| WO2003020906A2 (en) * | 2001-08-31 | 2003-03-13 | Abmaxis, Inc. | Multivalent protein conjugate with multiple ligand-binding domains of receptors |
| WO2005087812A1 (en) * | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
| CN1997382A (zh) * | 2004-05-05 | 2007-07-11 | 梅里麦克制药股份有限公司 | 调节生物活性的双特异性结合剂 |
| EP1910542B1 (en) * | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| US20090304719A1 (en) * | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
| PL2274008T3 (pl) * | 2008-03-27 | 2014-07-31 | Zymogenetics Inc | Kompozycje i sposoby hamowania PDGFRbeta i VEGF-A |
-
2010
- 2010-03-26 KR KR1020117025299A patent/KR20110134494A/ko not_active Ceased
- 2010-03-26 CN CN2010800230893A patent/CN102448984A/zh active Pending
- 2010-03-26 AU AU2010229705A patent/AU2010229705A1/en not_active Abandoned
- 2010-03-26 EP EP10722828A patent/EP2411407A1/en not_active Ceased
- 2010-03-26 US US13/260,408 patent/US20120134993A1/en not_active Abandoned
- 2010-03-26 JP JP2012502294A patent/JP2012521768A/ja active Pending
- 2010-03-26 WO PCT/US2010/028877 patent/WO2010111625A1/en not_active Ceased
- 2010-03-26 MX MX2011009810A patent/MX2011009810A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012521768A5 (OSRAM) | ||
| JP2009505676A5 (OSRAM) | ||
| Lafitte et al. | Roles of exosomes in metastatic colorectal cancer | |
| NZ594479A (en) | Diagnosis and treatment of gastric-type cancers with siRNA, modified antibodies, or immunotherapy approaches | |
| Wang et al. | Breast cancer stem cells: signaling pathways, cellular interactions, and therapeutic implications | |
| UA114108C2 (uk) | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання | |
| ME02692B (me) | NOVA IMUNOTERAPIJA PROTIV NEKOLIKO TUMORA UKLJUČUJUĆI GASTROINTESTINALNI KARCINOM l KARCINOM ŽELUCA | |
| WO2012097313A3 (en) | Therapeutic antibodies against ror-1 protein and methods for use of same | |
| RU2013104830A (ru) | Лечение рака при помощи направленных на мишень антител in vivo | |
| JP2012100677A5 (OSRAM) | ||
| PH12013500410B1 (en) | Vegf-binding molecules | |
| JP2019536426A5 (OSRAM) | ||
| JP2013166763A5 (OSRAM) | ||
| JP2010006705A5 (OSRAM) | ||
| UA99602C2 (ru) | Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток | |
| Singh et al. | Salinomycin inhibits epigenetic modulator EZH2 to enhance death receptors in colon cancer stem cells | |
| JPWO2020232303A5 (OSRAM) | ||
| RU2012143943A (ru) | КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ МЕТАСТАЗОВ РАКА, СОДЕРЖАЩАЯ СЛИТЫЙ БЕЛОК DLK1-Fc В КАЧЕСТВЕ ЭФФЕКТИВНОГО ИНГРЕДИЕНТА | |
| WO2011116212A3 (en) | Bone morphogenetic protein receptor binding agents and methods of their use | |
| CN104411825B (zh) | 骨膜蛋白适配体及包含其的抗癌组合物 | |
| You et al. | COMMD7 promotes hepatocellular carcinoma through regulating CXCL10 | |
| JP2020516668A5 (OSRAM) | ||
| Liang et al. | Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers | |
| WO2009124281A3 (en) | Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis | |
| Wei et al. | Identification of a novel therapeutic candidate, NRK, in primary cancer-associated fibroblasts of lung adenocarcinoma microenvironment |